Real-world safety study of Alhemo in hemophilia
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial will track how well Alhemo works and how safe it is for people with hemophilia A or B in everyday use. If you are 12 or older and your doctor has already decided to start you on Alhemo, this study will collect information to help doctors better understand the medicine's real-world benefits and risks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hemophilia A or hemophilia B
- You are 12 years of age or older
- You have never taken concizumab, or you just started it in the last 12 weeks
- You have not used any other experimental drug in the past 30 days
- You are not allergic to any ingredients in Alhemo
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is tracking how well Alhemo works in people with hemophilia A or B who have developed inhibitors (antibodies that block treatment). It is for patients of any age who have already started taking Alhemo as part of their regular care.
This trial is studying a medication called susoctocog alfa for people with acquired hemophilia A, a bleeding disorder. It aims to understand how well the treatment works and how it is being used.
This program gives access to concizumab, a medicine that helps prevent bleeding, for people with hemophilia who have inhibitors or can't use standard treatments. It's for when other options have not worked well.
This trial tests a study medicine (marstacimab) for children with severe hemophilia A or B, to see if it can help prevent or reduce bleeding episodes. It may be an option for children who do not have certain other health conditions.
This study tests a new medicine called denecimig (Mim8) for adults newly diagnosed with a rare bleeding disorder called acquired hemophilia A. If you have had a bleed that needs treatment, this trial could help you manage your condition.
This study looks at how well a newer preventive treatment for hemophilia A works in everyday life. It collects real-world information from patients to help doctors tailor clotting therapy better.
Hear when a new Haemophilia A, Haemophilia B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.